The audience at this meeting will be primarily comprised of European pharmaceutical professionals from the following disciplines: Pharmacovigilance Risk Management / Compliance Drug Safety / Clinical Safety QP / Deputy QP for Pharmacovigilance Regulatory Affairs Epidemiology Medical Affairs. Info: www.pharmacovigilance-events.com
Following revisions to existing regulations, recent drug recalls and increasing scrutiny of the role of pharmacovigilance, there has never been a more uncertain time for professionals involved in post-marketing drug safety. Leading experts from major pharmaceutical manufacturers and biotechs across Europe will be coming together this November in Berlin to discuss, debate and exchange solutions and best practice with a view to developing a world-class pharmacovigilance function. As you will see from the attached brochure, the agenda for Pharmacovigilance & Risk Management 2006 is both detailed and wide-ranging, providing you with two days of new, case study-based presentations on key issues such as: - Assessing the impact of the revised Volume 9 - Practical risk minimisation tools and techniques - Maintaining a viable PV service whilst managing increased workloads and constant change - Predicting and preparing for changing EU legislation - Ensuring that you are ready for pharmacovigilance inspections Experts will be sharing the latest thinking on pharmacovigilance best practice, and organisations such as Merck KGaA, Novartis Vaccines, Amgen, Eli Lilly, GlaxoSmithKline, SERVIER Group and BfArM will also be revealing their preparations for the evolution of this crucial function from. Reap the benefits of spending two intense days debating and discussing the key issues in the industry and make new business contacts – reserve your seat at this meeting straight away. (please quote reference MA on all communication)
